In order to assess potential effects of downregulated CD1d expression by tumor on innate and adaptive antitumor immunity, we assessed spleens from tumor-implanted mice for levels of iNKT, NK, CD4+ and CD8+ T cells by FACS. The gene discussed is CD8A; the disease is neoplasm.